STOCK TITAN

IOVANCE BIOTHERAPEUTICS (IOVA) SEC Filings, Mar 6-11, 2026

IOVA NASDAQ

Iovance Biotherapeutics, Inc. filings document a biotechnology company focused on polyclonal TIL therapies, including disclosures tied to Amtagvi, Proleukin, lifileucel, and broader solid-tumor cell therapy programs. Its Form 8-K reports cover operating results, financial condition, corporate presentations, clinical or regulatory disclosures, and material-event updates.

The filing record also includes proxy materials covering director elections, executive compensation, shareholder voting matters, and board governance. Capital-structure disclosures include common stock matters, registration-statement references, and material agreements related to an at-the-market offering program.

Rhea-AI Summary

Roche Corleen M. reported acquisition or exercise transactions in this Form 4 filing.

IOVANCE BIOTHERAPEUTICS, INC. reported that its Chief Financial Officer, Corleen M. Roche, received a grant of 132,200 restricted stock units (RSUs) on common stock as equity compensation. Each RSU represents the right to receive one share of common stock if vesting conditions are met.

These RSUs vest over three years, with one-third vesting on the one-year anniversary of the grant date. The remaining RSUs then vest in eight equal quarterly installments over the following two years, provided she remains employed with the company on each vesting date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.91%
Tags
insider
-
Rhea-AI Summary

Vogt Frederick G reported acquisition or exercise transactions in this Form 4 filing.

IOVANCE BIOTHERAPEUTICS, INC. granted Interim CEO & General Counsel Frederick G. Vogt 235,000 restricted stock units (RSUs) on March 9, 2026. Each RSU represents a contingent right to receive one share of Iovance common stock.

Vesting depends on continued employment. One-third of the RSUs will vest on the one-year anniversary of the grant date. The remaining RSUs will then vest in eight equal quarterly installments over the following two years, starting with the first quarter after the first anniversary.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.91%
Tags
insider
-
Rhea-AI Summary

Puri Raj K. reported acquisition or exercise transactions in this Form 4 filing.

IOVANCE BIOTHERAPEUTICS, INC. granted Chief Regulatory Officer Raj K. Puri 117,500 restricted stock units (RSUs) on common stock. Each RSU represents a right to receive one share if vesting conditions are met. The award vests over three years, with one-third vesting on the first anniversary of grant and the remaining two-thirds vesting in eight equal quarterly installments over the following two years, so long as he remains employed with the company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.91%
Tags
insider
Rhea-AI Summary

GRAF FINCKENSTEIN FRIEDRICH reported acquisition or exercise transactions in this Form 4 filing.

IOVANCE BIOTHERAPEUTICS, INC. reported that its Chief Medical Officer, Friedrich Graf Finckenstein, received a grant of 58,750 restricted stock units. Each RSU represents a contingent right to receive one share of common stock.

The RSUs vest over three years, assuming continued employment. One-third vests on the one-year anniversary of the grant date, and the remaining units vest in eight equal quarterly installments over the following two years. After this grant, the reporting person holds 58,750 RSUs directly.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.91%
Tags
insider
-
Rhea-AI Summary

Kirby Daniel Gordon reported acquisition or exercise transactions in this Form 4 filing.

IOVANCE BIOTHERAPEUTICS, INC. Chief Commercial Officer Daniel Kirby received a grant of 132,200 restricted stock units. Each RSU represents a contingent right to receive one share of common stock. After this grant, he holds 132,200 RSUs.

The RSUs vest over three years if he remains employed. One-third vests on the one-year anniversary of the grant date, and the remaining units vest in eight equal quarterly installments over the following two years.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.91%
Tags
insider
-
Rhea-AI Summary

BILINSKY IGOR reported acquisition or exercise transactions in this Form 4 filing.

Iovance Biotherapeutics reported that Chief Operating Officer Igor Bilinsky received a grant of 117,500 restricted stock units. Each RSU represents one share of common stock. The award vests over three years, with one-third vesting after one year and the balance in eight quarterly installments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.91%
Tags
insider
Rhea-AI Summary

IOVANCE BIOTHERAPEUTICS, INC. interim CEO and General Counsel Frederick G. Vogt reported equity compensation-related transactions. On March 5, 2026, 62,493 restricted stock units (RSUs) vested, converting into 62,493 shares of common stock at a stated price of $0.00 per share.

The company withheld 26,755 common shares at $4.58 per share to cover mandatory tax withholding on the RSU vesting, which is described as not an open market sale. After these transactions, Vogt directly owned 529,538 shares of common stock and 125,007 RSUs from the referenced grant.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.46%
Tags
insider
-
Rhea-AI Summary

IOVANCE BIOTHERAPEUTICS, INC. Chief Medical Officer Friedrich Graf Finckenstein reported equity compensation activity involving restricted stock units (RSUs) and common shares. On March 5, 2026, 31,246 RSUs vested, each converting into one share of common stock at a stated price of $0.00 per share.

Following the RSU vesting and conversion, 16,520 common shares were withheld by the company at $4.58 per share to satisfy mandatory tax withholding requirements, which the disclosure specifies is not an open market sale. After these transactions, Graf Finckenstein directly owned 131,957 shares of common stock and 62,504 RSUs from this grant, with the remaining RSUs scheduled to vest in equal quarterly installments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.46%
Tags
insider
-
Rhea-AI Summary

IOVANCE BIOTHERAPEUTICS Chief Regulatory Officer Raj K. Puri reported equity compensation activity involving restricted stock units and common stock. On the transaction date, 39,059 restricted stock units vested, each representing a right to receive one share of common stock, and were converted into 39,059 shares of Iovance common stock.

To cover mandatory tax withholding on the vesting, 18,360 shares of common stock were withheld by the company at a price of $4.58 per share. This withholding was not an open market sale of securities. After these transactions, Puri directly held 239,230 shares of common stock and 78,131 restricted stock units, with remaining RSUs scheduled to vest in equal quarterly installments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.46%
Tags
insider
Rhea-AI Summary

IOVANCE BIOTHERAPEUTICS, INC. Chief Operating Officer Igor Bilinsky reported the vesting of 31,246 restricted stock units on March 5, 2026, which were converted into an equal number of common shares at no exercise price.

To cover mandatory tax withholding on this RSU vesting, 16,628 common shares were withheld by the company at a reference price of $4.58 per share, which the disclosure states is not an open market sale. After these transactions, Bilinsky directly held 125,766 common shares and 62,504 RSUs. The remaining RSUs from this March 5, 2025 grant are scheduled to vest in equal quarterly installments, with each unit representing the right to receive one share of common stock.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.46%
Tags
insider

FAQ

How many IOVANCE BIOTHERAPEUTICS (IOVA) SEC filings are available on StockTitan?

StockTitan tracks 90 SEC filings for IOVANCE BIOTHERAPEUTICS (IOVA), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for IOVANCE BIOTHERAPEUTICS (IOVA)?

The most recent SEC filing for IOVANCE BIOTHERAPEUTICS (IOVA) was filed on November 13, 2026.